Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Cancer is a complex disease whose outcome depends largely on the cross-talk between the
tumor and its microenvironment. Here, we review the evolution of the field of tumor …

The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …

The overall response rate for anti–PD-1 therapy remains modest in hepatocellular
carcinoma (HCC). We found that a combination of IFNα and anti–PD-1–based …

The interferons (IFNs) are a family of cytokines that protect against disease by direct effects
on target cells and by activating immune responses. The production and actions of IFNs are …

Over the past decade, preclinical and clinical research have confirmed the essential role of
interferons for effective host immunological responses to malignant cells. Type I interferons …

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this
Review, we discuss accumulating evidence indicating that type I IFNs produced by …

Acute exposure of cancer cells to high concentrations of type I interferon (IFN-I) drives
growth arrest and apoptosis, whereas chronic exposure to low concentrations provides …

PARP7 is a monoPARP that catalyzes the transfer of single units of ADP-ribose onto
substrates to change their function. Here, we identify PARP7 as a negative regulator of …

Tumour-suppressor genes are indispensable for the maintenance of genomic integrity.
Recently, several of these genes, including those encoding p53, PTEN, RB1 and ARF, have …